| pubmed-article:21418106 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21418106 | lifeskim:mentions | umls-concept:C0033325 | lld:lifeskim |
| pubmed-article:21418106 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:21418106 | lifeskim:mentions | umls-concept:C0023452 | lld:lifeskim |
| pubmed-article:21418106 | lifeskim:mentions | umls-concept:C1706122 | lld:lifeskim |
| pubmed-article:21418106 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:21418106 | pubmed:dateCreated | 2011-5-18 | lld:pubmed |
| pubmed-article:21418106 | pubmed:abstractText | Objectives:? Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood; however, little is known of the molecular etiology and environmental exposures causing the disease. Cytochrome P450 3A5 (CYP3A5) plays a crucial role in the catalytic oxidation of endogenous metabolites and toxic substances, including chemotherapeutic agents. The aim of this study was to investigate the role of a single-nucleotide polymorphism (CYP3A5*3 6986A>G), which renders low enzyme activity, in the risk of developing ALL and in the outcome for children with ALL. Patients and methods:? Six hundred and sixteen childhood patients with ALL and 203 controls were genotyped by allelic discrimination. Results:? Individuals with the A allele had a 64% increased risk of developing childhood ALL (odds ratio = 1.64; 95% CI, 1.009-2.657). In general, event-free survival (EFS) did not differ in relation to CYP3A5 genotype. However, for patients with T-ALL, presence of the A allele was associated with better prognosis (EFS = 94.1%), while patients with the low-activity GG genotype only had an EFS of 61.5% (P = 0.015). Thus, for patients with T-ALL having no A allele and therefore low expression of CYP3A5, the risk of experiencing an event was almost eight times higher compared to those having at least one A allele (P = 0.045, hazard ratio = 7.749; 95% CI, 1.044-57.52). Conclusions:? This study shows that genetics may play a role in the risk of developing childhood ALL and indicates that improved treatment stratification of childhood patients with ALL may require addition of host genetic information. | lld:pubmed |
| pubmed-article:21418106 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21418106 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21418106 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21418106 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21418106 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21418106 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21418106 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21418106 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:21418106 | pubmed:issn | 1600-0609 | lld:pubmed |
| pubmed-article:21418106 | pubmed:author | pubmed-author:WesenbergFinn... | lld:pubmed |
| pubmed-article:21418106 | pubmed:author | pubmed-author:SchmiegelowKj... | lld:pubmed |
| pubmed-article:21418106 | pubmed:author | pubmed-author:DalhoffKimK | lld:pubmed |
| pubmed-article:21418106 | pubmed:author | pubmed-author:BorstLouiseL | lld:pubmed |
| pubmed-article:21418106 | pubmed:author | pubmed-author:WallerekSandr... | lld:pubmed |
| pubmed-article:21418106 | pubmed:author | pubmed-author:RasmussenKirs... | lld:pubmed |
| pubmed-article:21418106 | pubmed:author | pubmed-author:WehnerPeder... | lld:pubmed |
| pubmed-article:21418106 | pubmed:copyrightInfo | © 2011 John Wiley & Sons A/S. | lld:pubmed |
| pubmed-article:21418106 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21418106 | pubmed:volume | 86 | lld:pubmed |
| pubmed-article:21418106 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21418106 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21418106 | pubmed:pagination | 477-83 | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:meshHeading | pubmed-meshheading:21418106... | lld:pubmed |
| pubmed-article:21418106 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21418106 | pubmed:articleTitle | The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia. | lld:pubmed |
| pubmed-article:21418106 | pubmed:affiliation | Pediatric Clinic II, The Juliane Marie Centre, The University Hospital Rigshospitalet, Copenhagen. louise.borst@rh.regionh.dk | lld:pubmed |
| pubmed-article:21418106 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21418106 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:1577 | entrezgene:pubmed | pubmed-article:21418106 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:21418106 | lld:entrezgene |
